Fenofibrate/simvastatin fixed-dose combination in the treatment of mixed dyslipidemia: safety, efficacy, and place in therapy

References

• Global Burden of Disease Study 2013 CollaboratorsGlobal, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013Lancet201538674380026063472
   PubMed Web of Science ®Google Scholar
• EzzatiMLopezADRodgersAVander HoornSMurrayCJSelected major risk factors and global and regional burden of disease. Comparative Risk Assessment Collaborating GroupLancet20023601347136012423980
   PubMed Web of Science ®Google Scholar
• SharmaMGangulyNKPremature coronary artery disease in Indians and its associated risk factorsVasc Health Risk Manag2005121722517319107
   PubMedGoogle Scholar
• YusufSHawkenSOunpuuSEffect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control studyLancet200436493795215364185
   PubMed Web of Science ®Google Scholar
• NelsonRHHyperlipidemia as a risk factor for cardiovascular diseasePrim Care20134019521123402469
   PubMed Web of Science ®Google Scholar
• LacosteLLamJYHungJLetchacovskiGSolymossCBWatersDHyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reductionCirculation199592317231777586300
   PubMed Web of Science ®Google Scholar
• HossainPKawarBElNMObesity and diabetes in the developing world—a growing challengeN Engl J Med200735621321517229948
   PubMed Web of Science ®Google Scholar
• MemberSBrugerMExperimental atherosclerosis; the effect of feeding olive oil on the absorption and deposition of cholesterolArch Pathol194540373375
   Google Scholar
• QiQLiangLDoriaAHuFBQiLGenetic predisposition to dyslipidemia and type 2 diabetes risk in two prospective cohortsDiabetes20126174575222315312
   PubMed Web of Science ®Google Scholar
• VodnalaDRubenfireMBrookRDSecondary causes of dyslipidemiaAm J Cardiol201211082382522658245
   PubMed Web of Science ®Google Scholar
• ShepherdJCobbeSMFordIPrevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study GroupN Engl J Med1995333130113077566020
   PubMed Web of Science ®Google Scholar
• PedersenTRKjekshusJBergKRandomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)Lancet1994344138313897968073
   PubMed Web of Science ®Google Scholar
• CatapanoALReinerZDe BackerGESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)Atherosclerosis201121734621882396
   PubMed Web of Science ®Google Scholar
• StoneNJRobinsonJGLichtensteinAH2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice GuidelinesCirculation201412925 Suppl 2S1S4524222016
   PubMed Web of Science ®Google Scholar
• CannonCPCombination therapy in mixed dyslipidemiaJ Intern Med200826335365
   Web of Science ®Google Scholar
• LamarcheBLemieuxIDesprésJPThe small, dense LDL phenotype and the risk of coronary heart disease: epidemiology, patho-physiology and therapeutic aspectsDiabetes Metab19992519921110499189
   PubMed Web of Science ®Google Scholar
• HalcoxJMisraAType 2 diabetes mellitus, metabolic syndrome, and mixed dyslipidemia: how similar, how different, and how to treat?Metab Syndr Relat Disord20151312125402738
   PubMed Web of Science ®Google Scholar
• BrunzellJDIncreased ApoB in Small Dense LDL Particles Predicts Premature Coronary Artery DiseaseArterioscler Thromb Vasc Biol20052547447515731485
   PubMed Web of Science ®Google Scholar
• ShimabukuroMHigaNMasuzakiHSataMUedaSImpact of individual metabolic risk components or its clustering on endothelial and smooth muscle cell function in menCardiovasc Diabetol2016157727188597
   PubMed Web of Science ®Google Scholar
• KraussRMBurkeDJIdentification of multiple subclasses of plasma low density lipoproteins in normal humansJ Lipid Res198223971047057116
   PubMed Web of Science ®Google Scholar
• LamarcheBTchernofACantinBDagenaisGRLupienPJDesprésJPSmall, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular StudyCirculation19979569758994419
   PubMed Web of Science ®Google Scholar
• JacobsMJKleisliTPioJRMalikSL’ItalienGJChenRSWongNDPrevalence and control of dyslipidemia among persons with diabetes in the United StatesDiabetes Res Clin Pract20057026326915890427
   PubMed Web of Science ®Google Scholar
• YounisNNSoranHPembertonPCharlton-MenysVElseweidyMMDurringtonPNSmall dense LDL is more susceptible to glycation than more buoyant LDL in Type 2 diabetesClin Sci201312434334922985435
   PubMed Web of Science ®Google Scholar
• AgouridisAPRizosCVElisafMSFilippatosTDDoes combination therapy with statins and fibrates prevent cardiovascular disease in diabetic patients with atherogenic mixed dyslipidemia?Rev Diabet Stud20131017119024380091
   PubMedGoogle Scholar
• GittAKJungerCSmolkaWBestehornKPrevalence and overlap of different lipid abnormalities in statin-treated patients at high cardiovascular risk in clinical practice in GermanyClin Res Cardiol20109972373320521058
   PubMed Web of Science ®Google Scholar
• MauroVFClinical pharmacokinetics and practical applications of simvastatinClin Pharmacokinet1993241952028343198
   PubMed Web of Science ®Google Scholar
• MyersonMNgaiCJonesJHolleranSRamakrishnanRBerglundLGinsbergHNTreatment with high-dose simvastatin reduces secretion of apolipoprotein B-lipoproteins in patients with diabetic dyslipidemiaJ Lipid Res2005462735274416162940
   PubMed Web of Science ®Google Scholar
• NawrockiJWWeissSRDavidsonMHReduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitorArterioscler Thromb Vasc Biol19951556786827749881
   PubMed Web of Science ®Google Scholar
• FarnierMPortalJJMaigretPEfficacy of atorvastatin compared with simvastatin in patients with hypercholesterolemiaJ Cardiovasc Pharmacol Ther200051273210687671
   PubMedGoogle Scholar
• KapurNKMusunuruKClinical efficacy and safety of statins in managing cardiovascular riskVasc Health Risk Manag20084234135318561510
   PubMedGoogle Scholar
• OseLDavidsonMHSteinEALipid-altering efficacy and safety of simvastatin 80 mg/day: long-term experience in a large group of patients with hypercholesterolemia. World Wide Expanded Dose Simvastatin Study GroupClin Cardiol2000231394610680028
   PubMed Web of Science ®Google Scholar
• HunninghakeDBBallantyneCMMaccubbinDLShahAKGumbinerBMitchelYBComparative effect of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A1Clin Ther2003251670168612860491
   PubMed Web of Science ®Google Scholar
• SerraNRosalesRMasanaLVallvéJCSimvastatin increases fibulin-2 expression in human coronary artery smooth muscle cells via rhoA/rho-kinase signaling pathway inhibitionPLoS One201510e013387526207907
   PubMed Web of Science ®Google Scholar
• BellostaSViaDCanavesiMPfisterPFumagalliRPaolettiRBerniniFHMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophagesArterioscler Thromb Vasc Biol199818167116789812903
   PubMed Web of Science ®Google Scholar
• MeredithKGHorneBDPearsonRRMaycockCALappeDLAndersonJLMuhlesteinJBComparison of effects of high (80 mg) versus low (20 mg) dose of simvastatin on C-reactive protein and lipoproteins in patients with angiographic evidence of coronary arterial narrowingAm J Cardiol20079914915317223409
   PubMed Web of Science ®Google Scholar
• ZouCQiHLiuZHHanLZhaoCYangXSimvastatin activates the PPARγ-dependent pathway to prevent left ventricular hypertrophy associated with inhibition of RhoA signalingTex Heart Inst J20134014014723678211
   PubMed Web of Science ®Google Scholar
• AlmansobMAXuBZhouLSimvastatin reduces myocardial injury undergoing noncoronary artery cardiac surgery: a randomized controlled trialArterioscler Thromb Vasc Biol2012322304231322796581
   PubMed Web of Science ®Google Scholar
• PedersenTRKjekshusJBergKRandomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)Lancet1994344138313897968073
   PubMed Web of Science ®Google Scholar
• Heart Protection Study Collaborative GroupMRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trialLancet200236072212114036
   PubMed Web of Science ®Google Scholar
• MAAS investigatorsEffect of simvastatin on coronary atheroma: the multicentre anti-atheroma study (MAAS)Lancet19943446336387864934
   PubMed Web of Science ®Google Scholar
• SattarNPreissDMurrayHStatins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trialsLancet201037573574220167359
   PubMed Web of Science ®Google Scholar
• AbbasiSHMohammadinejadPShahmansouriNSimvastatin versus atorvastatin for improving mild to moderate depression in post-coronary artery bypass graft patients: a double-blind, placebo-controlled, randomized trialJ Affect Disord201518314915526005776
   PubMed Web of Science ®Google Scholar
• KretzerIFMariaDAGuidoMCContenteTCMaranhãoRCSimvastatin increases the antineoplastic actions of paclitaxel carried in lipid nanoemulsions in melanoma-bearing miceInt J Nanomedicine20161188590427022257
   PubMed Web of Science ®Google Scholar
• McKeageKKeatingGMFenofibrate: a review of its use in dyslipidaemiaDrugs2011711917194621942979
   PubMed Web of Science ®Google Scholar
• SchoonjansKPeinado-OnsurbeJLefebvreAMPPAR alpha and PPAR gamma activators direct a distinct tissue-specific transcriptional response via PPRE in the lipoprotein lipase geneEMBO J199615533653488895578
   PubMed Web of Science ®Google Scholar
• FarnierMUpdate on the clinical utility of fenofibrate in mixed dyslipidemias: mechanisms of action and rational prescribingVasc Health Risk Manag20084991100019183747
   PubMedGoogle Scholar
• LinzPELovatoLCByingtonRPParadoxical reduction in HDL-C with fenofibrate and thiazolidinedione therapy in type 2 diabetes: the ACCORD Lipid TrialDiabetes Care20143768669324296848
   PubMed Web of Science ®Google Scholar
• MussoGCassaderMGambinoRCholesterol-lowering therapy for the treatment of nonalcoholic fatty liver disease: an updateCurr Opin Lipidol20112248949621986643
   PubMed Web of Science ®Google Scholar
• KrysiakRStachura-KulachAOkopienBMetabolic and monocyte-suppressing actions of fenofibrate in patients with mixed dyslipidemia and early glucose metabolism disturbancesPharmacol Rep20106212013020360622
   PubMed Web of Science ®Google Scholar
• PruskiMKrysiakROkopienBPleiotropic action of short-term metformin and fenofibrate treatment, combined with lifestyle intervention, in type 2 diabetic patients with mixed dyslipidemiaDiabetes Care2009321421142419435959
   PubMed Web of Science ®Google Scholar
• Idzior-WalusBSieradzkiJRostworowskiWEffects of comicronised fenofibrate on lipid and insulin sensitivity in patients with polymetabolic syndrome XEur J Clin Invest20003087187811029601
   PubMed Web of Science ®Google Scholar
• KrysiakRGdula-DymekAOkopienBThe effect of fenofibrate on lymphocyte release of proinflammatory cytokines and systemic inflammation in simvastatin-treated patients with atherosclerosis and early glucose metabolism disturbancesBasic Clin Pharmacol Toxicol201311219820222935083
   PubMed Web of Science ®Google Scholar
• FilippatosTDElisafMSSafety considerations with fenofibrate/simvastatin combinationExpert Opin Drug Saf2015141481149326134595
   PubMed Web of Science ®Google Scholar
• YeJKiageJNArnettDKBartolucciAAKabagambeEKShort-term effect of fenofibrate on C-reactive protein: a meta-analysis of randomized controlled trialsDiabetol Metab Syndr201132421939559
   PubMed Web of Science ®Google Scholar
• KeechASimesRJBarterPEffects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trialLancet20053661849186116310551
   PubMed Web of Science ®Google Scholar
• ScottRO’BrienRFulcherGEffects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) studyDiabetes Care20093249349818984774
   PubMed Web of Science ®Google Scholar
• SteinerGThe Diabetes Atherosclerosis Intervention Study (DAIS): a study conducted in cooperation with the World Health Organization. The DAIS Project GroupDiabetologia199639165516619081851
   PubMed Web of Science ®Google Scholar
• GinsbergHNElamMBLovatoLCThe ACCORD Study GroupEffects of combination lipid therapy in type 2 diabetes mellitusN Engl J Med20103621563157420228404
   PubMed Web of Science ®Google Scholar
• ElamMLovatoLCGinsbergHRole of fibrates in cardiovascular disease prevention, the ACCORD-Lipid perspectiveCurr Opin Lipidol201122556121102326
   PubMed Web of Science ®Google Scholar
• The ACCORD Study Group and ACCORD Eye Study GroupEffects of medical therapies on retinopathy progression in type 2 diabetesN Engl J Med201036323324420587587
   PubMed Web of Science ®Google Scholar
• Reyes-SofferGNgaiCILovatoLKarmallyWRamakrishnanRHolleranSGinsbergHNEffect of combination therapy with fenofibrate and simvastatin on postprandial lipemia in the ACCORD lipid trialDiabetes Care20133642242823033246
   PubMed Web of Science ®Google Scholar
• BansalSBuringJERifaiNMoraSSacksFMRidkerPMFasting compared with nonfasting triglycerides and risk of cardiovascular events in womenJAMA200729830931617635891
   PubMed Web of Science ®Google Scholar
• NordestgaardBGBennMSchnohrPTybjærg-HansenANonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and womenJAMA200729829930817635890
   PubMed Web of Science ®Google Scholar
• GrundySMVegaGLYuanZBattistiWPBradyWEPalmisanoJEffectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial)Am J Cardiol20059546246815695129
   PubMed Web of Science ®Google Scholar
• GrundySMVegaGLTomassiniJETershakovecAMCorrelation of non-high-density lipoprotein cholesterol and low-density lipoprotein cholesterol with apolipoprotein B during simvastatin + fenofibrate therapy in patients with combined hyperlipidemia (a subanalysis of SAFARI trial)Am J Cardiol200910454855319660610
   PubMed Web of Science ®Google Scholar
• MohiuddinSMPepineCJKellyMTButtlerSMSetzeCMSleepDJStolzenbachJCEfficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: a phase 3, randomized, controlled studyAm Heart J200915719520319081418
   PubMed Web of Science ®Google Scholar
• MuhlesteinJBMayHTJensenJRThe reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia: the DIACOR (Diabetes and Combined Lipid Therapy Regimen) studyJ Am Coll Cardiol20064839640116843192
   PubMed Web of Science ®Google Scholar
• MayHTAndersonJLPearsonRRComparison of effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in diabetic patients with mixed dyslipidemia (from the Diabetes and Combined Lipid Therapy Regimen study)Am J Cardiol200810148648918312763
   PubMed Web of Science ®Google Scholar
• StefanuttiCBucciADi GiacomoSEfficacy, safety and tolerability of combined low-dose simvastatin-fenofibrate treatment in primary mixed hyperlipidaemiaClin Drug Investig200424465477
   PubMed Web of Science ®Google Scholar
• KayikçioğluMOzerkanFSoydanIEffectiveness and safety of alternate-day simvastatin and fenofibrate on mixed hyperlipidemiaAm J Cardiol19998311351137A910190536
   PubMed Web of Science ®Google Scholar
• FoucherCAubonnetPReichertPNew fixed-dose combinations of fenofibrate/simvastatin therapy significantly improve the lipid profile of high-risk patients with mixed dyslipidemia versus monotherapiesCardiovasc Ther20153332933726227087
   PubMed Web of Science ®Google Scholar
• ShahHDParikhKHChagMCBeneficial effects of the addition of fenofibrate to statin therapy in patients with acute coronary syndrome after percutaneous coronary interventionsExp Clin Cardiol200712919618650989
   PubMedGoogle Scholar
• SahebkarASerbanMCMikhailidisDPHead-to-head comparison of statins versus fibrates in reducing plasma fibrinogen concentrations: a systematic review and meta-analysisPharmacol Res201610323625226657419
   PubMed Web of Science ®Google Scholar
• XuQYLiuYHZhangQMetabolomic analysis of simvastatin and fenofibrate intervention in high-lipid diet-induced hyperlipidemia ratsActa Pharmacol Sin2014351265127325220639
   PubMed Web of Science ®Google Scholar
• KrysiakRGdula-DymekAOkopienBEffect of simvastatin and fenofibrate on cytokine release and systemic inflammation in type 2 diabetes mellitus with mixed dyslipidemiaAm J Cardiol20111071010101821276586
   PubMed Web of Science ®Google Scholar
• BannwarthBDrug-induced myopathiesExpert Opin Drug Saf20021657012904161
   PubMedGoogle Scholar
• TomaszewskiMStępieńKMTomaszewskaJCzuczwarSJStatin-induced myopathiesPharmacol Rep20116385986622001973
   PubMed Web of Science ®Google Scholar
• MammenALStatin-associated autoimmune myopathyN Engl J Med201637466466926886523
   PubMed Web of Science ®Google Scholar
• CalderonRMCubedduLXGoldbergRBSchiffERStatins in the treatment of dyslipidemia in the presence of elevated liver aminotransferase levels: a therapeutic dilemmaMayo Clin Proc20108534935620360293
   PubMed Web of Science ®Google Scholar
• PettersenJCPruimboom-BreesIFranconeOLAmacherDEBoldtSEKerlinRLBallingerWEThe PPARα agonists fenofibrate and CP-778875 cause increased β-oxidation, leading to oxidative injury in skeletal and cardiac muscle in the ratToxicol Pathol20124043544722301950
   PubMed Web of Science ®Google Scholar
• BalfourJAMcTavishDHeelRCFenofibrate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemiaDrugs1990402602902226216
   PubMed Web of Science ®Google Scholar
• KobayashiASuzukiYKunoHSugaiSSakakibaraHShimoiKEffects of fenofibrate on plasma and hepatic transaminase activities and hepatic transaminase gene expression in ratsJ Toxicol Sci20093437738719652460
   PubMed Web of Science ®Google Scholar
• PattersonADShahYMMatsubaraTKrauszKWGonzalezFJPeroxisome proliferator-activated receptor alpha induction of uncoupling protein 2 protects against acetaminophen-induced liver toxicityHepatology20125628129022318764
   PubMed Web of Science ®Google Scholar
• ScottRO’BrienRFulcherGEffects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) studyDiabetes Care20093249349818984774
   PubMed Web of Science ®Google Scholar
• NoéJPortmannRBrunMEFunkCSubstrate-dependent drug-drug interactions between gemfibrozil, fluvastatin and other organic anion-transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and OATP1B3Drug Metab Dispos2007351308131417470528
   PubMed Web of Science ®Google Scholar
• WinsemiusAAnsquerJCOlbrichMPharmacokinetic interaction between simvastatin and fenofibrate with staggered and simultaneous dosing: does it matter?J Clin Pharmacol2014541038104724691799
   PubMedGoogle Scholar
• CohenDEAnaniaFAChalasaniNAn assessment of statin safety by hepatologistsAm J Cardiol20069777C81C16377288
   PubMed Web of Science ®Google Scholar
• GuoJMengFMaNMeta-analysis of safety of the coadministration of statin with fenofibrate in patients with combined hyper-lipidemiaAm J Cardiol20121101296130122840347
   PubMed Web of Science ®Google Scholar
• Food and Drug AdministrationFDA drug safety communication: review update of Trilipix (fenofibric acid) and the ACCORD Lipid trial1192011 Available from: http://www.fda.gov/Drugs/DrugSafety/ucm278837.htmlAccessed June 22, 2016
   Google Scholar
• CurtinPOJonesWNTherapeutic rationale of combining therapy with gemfibrozil and simvastatinJ Am Pharm Assoc200747140146
   Google Scholar
• HorsmansYDesagerJPHarvengtCEffects of combined bezafibrate-simvastatin appraised in healthy subjectsJ Clin Pharmacol1992324224261587959
   PubMed Web of Science ®Google Scholar
• KehelyAMacMahonMBarbirMWrayRHuntBJPrescottRJThompsonGRCombined bezafibrate and simvastatin treatment for mixed hyperlipidaemiaQJM199588749
   Web of Science ®Google Scholar
• FarnierMDejagerSEffect of combined fluvastatin-fenofibrate therapy compared with fenofibrate monotherapy in severe primary hypercholesterolemia. French Fluvastatin Study GroupAm J Cardiol200085535711078237
   PubMed Web of Science ®Google Scholar
• FarnierMSteinmetzARetterstølKCsászárAFixed-dose combination fenofibrate/pravastatin 160/40 mg versus simvastatin 20 mg monotherapy in adults with type 2 diabetes and mixed hyperlipidemia uncontrolled with simvastatin 20 mg: a double-blind, randomized comparative studyClin Ther20113311221397769
   PubMed Web of Science ®Google Scholar
• AthyrosVGPapageorgiouAAAthyrouVVDemitriadisDSKontopoulosAGAtorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemiaDiabetes Care200225119820212087019
   PubMed Web of Science ®Google Scholar
• ChenYPChangKCTsengWKYinWHChenJWLeeYTWuCCIncreased rosuvastatin dose versus concomitant fenofibrate and rosuvastatin therapy to achieve lipid goal in patients with diabetes or atherosclerosis with metabolic syndromeZhonghua Minguo Xin Zang Xue Hui Za Zhi201329421428
   Google Scholar
• KeiALiberopoulosEElisafMEffect of hypolipidemic treatment on glycemic profile in patients with mixed dyslipidemiaWorld J Diabetes2013436537124379928
   PubMedGoogle Scholar
• VegaGLMaPTCaterNBFilipchukNMeguroSGarcia-GarciaABGrundySMEffects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndromeAm J Cardiol20039195696012686335
   PubMed Web of Science ®Google Scholar
• LedlMHoheneckerJFrancesconiCRootsIBauerMFRodenMAcute myopathy in a type 2 diabetic patient on combination therapy with metformin, fenofibrate and rosiglitazoneDiabetologia2005481996199816132947
   PubMed Web of Science ®Google Scholar
• ChertowBSMottoGSShahJHA biochemical profile of abnormalities in hypothyroidismAm J Clin Pathol1974617857884832117
   PubMed Web of Science ®Google Scholar
• SindoniARodolicoCPappalardoMAPortaroSBenvengaSHypothyroid myopathy: a peculiar clinical presentation of thyroid failure. Review of the literatureRev Endocr Metab Disord Epub201657
   PubMed Web of Science ®Google Scholar
• KiernanTJRochfordMMcDermottJHSimvastatin induced rhab-domyolysis and an important clinical link with hypothyroidismInt J Cardiol200711937437617098308
   PubMed Web of Science ®Google Scholar
• QariFASevere rhabdomyolysis and acute renal failure secondary to the use of simvastatin in undiagnosed hypothyroidismIndian J Nephrol200818282920368919
   PubMedGoogle Scholar
• ClouâtreYLeblancMOuimetDPichetteVFenofibrate-induced rhabdomyolysis in two dialysis patients with hypothyroidismNephrol Dial Transplant1999141047104810328516
   PubMed Web of Science ®Google Scholar
• FeeneyERMallonPWGHIV and HAART-associated dyslipidemiaOpen Cardiovasc Med J20115496321643501
   PubMedGoogle Scholar
• EhnholmCAhoKHuttunenJKKostiainenEMattilaKPakkarainenJCantellKEffect of interferon on plasma lipoproteins and on the activity of post heparin plasma lipasesArteriosclerosis1982268736174110
   PubMedGoogle Scholar
• VuCNRuiz-EspondaRYangEAltered relationship of plasma triglycerides to HDL cholesterol in patients with HIV/HAART-associated dyslipidemia: further evidence for a unique form of metabolic syndrome in HIV patientsMetabolism2013621014102023522788
   PubMed Web of Science ®Google Scholar
• LumYDHeJGSlatterJGGene expression profiling of rat liver reveals a mechanistic basis for ritonavir-induced hyperlipidemiaGenomics20079046447317719200
   PubMed Web of Science ®Google Scholar
• PenzakSRChuckSKManagement of protease inhibitor-associated hyperlipidemiaAm J Cardiovasc Drugs200229110614727985
   PubMedGoogle Scholar
• VisnegarwalaFMaldonadoMSajjaPLipid lowering effects of statins and fibrates in the management of HIV dyslipidemias associated with antiretroviral therapy in HIV clinical practiceJ Infect20044928329015474625
   PubMed Web of Science ®Google Scholar
• HusainNEAhmedMHManaging dyslipidemia in HIV/AIDS patients: challenges and solutionsHIV AIDS20147110
   Google Scholar
• FeinsteinMJAchenbachCJStoneNJLloyd-JonesDMA systematic review of the usefulness of statin therapy in HIV-infected patientsAm J Cardiol20151151760176625907504
   PubMed Web of Science ®Google Scholar
• KaveyRECombined dyslipidemia in childhoodJ Clin Lipidol201595 SupplS41S5626343211
   PubMed Web of Science ®Google Scholar
• StefanuttiCLucaniGVivenzioADi GiacomoSDiet only and diet plus simvastatin in the treatment of heterozygous familial hypercholesterolemia in childhoodDrugs Exp Clin Res199925232810337501
   PubMedGoogle Scholar
• SteinmetzJMorinCPanekESiestGDrouinPBiological variations in hyperlipidemic children and adolescents treated with fenofibrateClin Chim Acta198111243536113065
   PubMed Web of Science ®Google Scholar